SOPHiA GENETICS SA (SOPH) is a global health tech company that is leading the charge in data-driven medicine. The company uses artificial intelligence (AI) to analyze genetic data and improve patient outcomes across a broad spectrum of diseases. SOPHiA GENETICS, which combines deep learning algorithms and genomic big data, was established with the mission to democratize data-driven medicine so that everyone can benefit.
SOPHiA GENETICS was founded in Switzerland in 2011 by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, and quickly established itself as a pioneer in data-driven medicine. The company’s AI, known as SOPHiA, is an advanced system that learns from every genomic sequencing it processes, making it smarter and more efficient with each use. The firm provides technology to over 1,000 hospitals in more than 80 countries, decoding human genome and helping clinicians better diagnose and treat patients.
The company focuses on oncology and hereditary disorders, with its innovative technology analyzing DNA sequencing data to detect molecular alterations or genetic mutations that may cause diseases. By predicting the impact of these genetic variations and detecting biomarkers for disease, SOPHiA GENETICS can support clinical researchers and healthcare professionals in their patient care decisions.
SOPHiA's unique AI platform allows for high-precision, scalable, and robust genomic analysis, giving its partners an unparalleled edge in clinical diagnostics and therapeutics. The company's AI algorithms can accurately detect and quantify complex genetic variants, such as point mutations, copy number alterations, and structural variants, making it a trusted resource for genome analysis and interpretation.
The company aims to empower medical professionals and help patients around the world through the implementation of its complex AI algorithms and extensive genetic databases. As the leading force in data-driven medicine, SOPHiA GENETICS SA is expanding the boundaries of the medical field and contributing significantly to personalised medicine, leading the fight against complex genetic diseases and cancer.
SOPHiA GENETICS is publicly traded with the ticker symbol SOPH and has continuously shown growth, a testament to its innovative technology and vision. The company also works in close collaboration with biopharmaceutical companies and academic institutions worldwide, further contributing to its reputation as a trusted, leading player in the genomic healthcare sector. With a strong commitment to transforming healthcare through technology, SOPHiA GENETICS SA continues to prove its worth in the ever-evolving health tech space.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Sophia Genetics reported strong Q3 2026 results with 25% year-over-year revenue growth, driven by demand in the U.S. and adoption of new liquid biopsy and solid tumor products. The company significantly improved adjusted EBITDA by 31%, reflecting effective cost management and a commitment to profitable growth. Sophia Genetics raised its full-year 2026 revenue guidance to the upper end of $94 million to $96 million, while reiterating its adjusted EBITDA loss guidance, anticipating continued strong performance despite foreign exchange headwinds.
Sowell Financial Services LLC has acquired a new stake of 341,889 shares in SOPHiA GENETICS SA (NASDAQ:SOPH), valued at approximately $2.87 million, bringing their total ownership to 0.41%. This comes as institutional investors collectively own 31.59% of the company, while insiders have sold over $1.94 million worth of shares in the past three months. SOPH shares opened down 4.3% at $7.63, and analysts maintain a consensus "Hold" rating with a $10 price target despite a recent quarterly loss per share that missed estimates.
SOPHiA GENETICS (NASDAQ: SOPH) is projected to announce its Q3 2026 earnings before market open on Tuesday, November 3rd, with analysts forecasting a loss of $0.198 per share and revenue of $24.03 million. The company missed EPS expectations in the previous quarter but exceeded revenue estimates. Analyst sentiment remains mixed with a consensus "Hold" rating and a $10 average price target, while insiders have sold approximately $1.94 million in stock over the past 90 days.
SOPHiA GENETICS (Nasdaq: SOPH) announced it will release its financial results for the third quarter of 2026 on Tuesday, November 3, 2026, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. EDT / 2:00 p.m. CET on the same day to discuss the results and business outlook. A replay of the call will be available on the SOPHiA GENETICS Investor Relations Website.
Jurgi Camblong, Executive Chairman and Director of SOPHiA GENETICS SA (NASDAQ:SOPH), sold 8,500 ordinary shares on October 12, 2026. The sale was executed under a Rule 10b5-1 trading plan at a weighted average price of $7.2554 per share, with individual transaction prices ranging from $7.15 to $7.38. Following this transaction, Camblong directly retains 3,387,150 ordinary shares.
SOPHiA GENETICS insider Zhenyu Xu sold 4,000 shares of the company's stock for $28,720 on October 13, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. This sale decreased Xu's ownership by 0.73%, though they still hold over 541,000 shares. The stock traded at $7.06, and despite missing EPS estimates, the company exceeded revenue forecasts.
SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the company's stock for $61,710 under a pre-arranged Rule 10b5-1 trading plan. This transaction, along with other recent sales, reduced his holdings to 3.39 million shares. The company's stock traded down 0.4% to $7.06, and while its latest quarterly revenue exceeded expectations, it missed EPS estimates.